Benefits of Prophylactic Short-Course Immune Tolerance Induction in Patients With Infantile Pompe Disease: Demonstration of Long-Term Safety and Efficacy in an Expanded Cohort

Immune tolerance induction (ITI) with a short-course of rituximab, methotrexate, and/or IVIG in the enzyme replacement therapy (ERT)-naïve setting has prolonged survival and improved clinical outcomes in patients with infantile Pompe disease (IPD) lacking endogenous acid-alpha glucosidase (GAA), kno...

Descripción completa

Detalles Bibliográficos
Autores principales: Desai, Ankit K., Baloh, Carolyn H., Sleasman, John W., Rosenberg, Amy S., Kishnani, Priya S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7424004/
https://www.ncbi.nlm.nih.gov/pubmed/32849613
http://dx.doi.org/10.3389/fimmu.2020.01727

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7424004/
https://www.ncbi.nlm.nih.gov/pubmed/32849613
http://dx.doi.org/10.3389/fimmu.2020.01727

Ejemplares similares